A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Annals of Oncology, May 2016

B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, et al.

Article PDF cannot be displayed. You can download it here:

https://annonc.oxfordjournals.org/content/27/6/1180.full.pdf

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Annals of Oncology 27: 1180, 2016 doi:10.1093/annonc/mdw095 Published online 3 March 2016 corrigenda A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer B. H. O’Neil, A. J. Scott, W. W. Ma, S. J. Cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, A. L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. Radford, L. Fehrenbacher, R. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes & W. A. Messersmith The correct author list is as above. corrigenda In the original article, author A. L. Coveler was incorrectly listed as L. Coveler. © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: . Ann Oncol 2015; 26: 1923–1929 (doi: 10.1093/annonc/ mdv264) (...truncated)


This is a preview of a remote PDF: https://annonc.oxfordjournals.org/content/27/6/1180.full.pdf
Article home page: http://annonc.oxfordjournals.org/content/27/6/1180.extract

B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, A. L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. Radford, L. Fehrenbacher, R. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes, W. A. Messersmith. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer, Annals of Oncology, 2016, pp. 1180-1180, 27/6, DOI: 10.1093/annonc/mdw095